Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens

Annals of Pharmacotherapy

Volumn 45, Issue 3, 2011, Pages 317-324

  Patel, Nimish ^a   Abdelsayed, Sandra ^a   Veve, Michael ^a   Miller, Christopher D ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

Antiretroviral; Drug interaction; HIV

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CALCIUM CHANNEL BLOCKING AGENT; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; ETRAVIRINE; FLUTICASONE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHADONE; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; TAMSULOSIN; TENOFOVIR;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; COMPUTER PROGRAM; CROSS-SECTIONAL STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT CONTRAINDICATION;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; FEMALE; FORECASTING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 79952656222     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P576     Document Type: Article

References (18)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 2010 Aug 30).
2. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23:1109-18. DOI 10.1097/QAD.0b013e32832b4377
3. Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010;55:39-48. DOI 10.1097/QAI.0b013e3181da1287
4. Puls RL, Srasuebkul P, Petoumenos K, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis 2010;51:855-64. DOI 10.1086/656363
5. Miller CD, El-Kholi R, Faragon JJ, Lodise TP. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacotherapy 2007;27:1379-86. DOI 10.1592/phco.27.10.1379 (Pubitemid 47530444)
6. Park-Wyllie LY, Levine MA, Holbrook A, et al. Outcomes of dosage adjustments used to manage antiretroviral drug interactions. Clin Infect Dis 2007;45:933-6. DOI 10.1086/521252 (Pubitemid 47580391)
7. Valin N, De Castro N, Garrait V, Bergeron A, Bouche C, Molina JM. Iatrogenic Cushing's syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone: description of 4 new cases and review of the literature. J Int Assoc Physicians AIDS Care (Chic) 2009;8:113-21. DOI 10.1177/ 1545109709332019
8. Baeza MT, Merino E, Boix V, Climent E. Nifedipine-lopinavir/ritonavir severe interaction: a case report. AIDS 2007;21:119-20. DOI 10.1097/QAD. 0b013e3280117f6f (Pubitemid 44912552)
9. Cheng CH, Miller C, Lowe C, Pearson VE. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm 2002;59:728-30. (Pubitemid 34407159)
10. Pinzani V, Faucherre V, Peyriere H, Blayac JP. Methadone withdrawal symptoms with nevirapine and efavirenz. Ann Pharmacother 2000;34:405-7. (Pubitemid 30133611)
11. Negredo E, Molto J, Burger D, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004;18:459-63. (Pubitemid 38365873)
12. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007;35:1657-63. DOI 10.1124/dmd.107.016196 (Pubitemid 47296061)
13. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS clinical trials group 5108 Study. J Acquir Immune Defic Syndr 2005;39:307-12. (Pubitemid 40923210)
14. Iwamoto M, Kassahun K, Troyer MD, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol 2008;48:209-14. DOI 10.1177/0091270007310382
15. Koudriakova T, Iatsimirskaia E, Utkin I, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 1998;26:552-61. (Pubitemid 28498361)
16. Lexi-Interact. Hudson, OH: Lexi-Comp Inc. (accessed 2010 May 6-10).
17. Evans-Jones JG, Cottle LE, Back DJ, et al. Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2010;50:1419-21. DOI 10.1086/652149
18. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010;87:322-9. DOI 10.1038/clpt.2009.228